Navigation Links
Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
Date:2/14/2013

BRISBANE, Calif., Feb. 14, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Sean P. Nolan has joined InterMune as Executive Vice President and Chief Business Officer.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

In this newly created position, Mr. Nolan will lead the creation and establishment of InterMune's U.S. Commercial, Business Development and Global Marketing groups. He will also oversee InterMune's Canadian operations and the company's Manufacturing Operations and Supply Chain Management. Mr. Nolan will report to Dan Welch , Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Sean will play a key role in InterMune's future as our Esbriet sales continue to grow globally, we move closer to the anticipated approval and launch of Esbriet in the United States and as we prepare to develop our business. I am confident that Sean will provide the broad and deep commercial and business experience, energy and drive that are essential during this exciting period of growth and change for our company."

Mr. Nolan began his career at Abbott Laboratories in 1991 and during a period of 13 years served in a variety of marketing and sales leadership positions. In 2004, he joined Ovation Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of therapies to treat rare diseases. At Ovation, Sean developed and implemented the commercial strategies for the orphan drug pipeline and subsequently led the organization's effort that resulted in FDA approval of the company's lead compound. Ovation was acquired by the Danish pharmaceutical company, H. Lundbeck in 2009. After leading the company integration process, Mr. Nolan served as President of the newly created U.S. entity of Lundbeck. While at Lundbeck, Mr. Nolan served on the board of the Tuberous Sclerosis Alliance, and was co-chair of the Rare and Specialty Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr. Nolan joins InterMune from Reata Pharmaceuticals, where he most recently served as Vice President and Chief Commercial Officer and built a commercial operation to support the company's lead product. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Appoints Michael Nolan Vice President, Chief Financial Officer and Treasurer
2. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
3. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
4. Natalie Douglas, CEO of Idis, Joins Global Genes
5. RARE Project Board of Directors
6. Breast Imaging Specialist Dr. Catherine D. Buhler Joins Radiologic Associates of Fredericksburg
7. Stephen Ondra, M.D., Joins Health Care Service Corporation As Enterprise Chief Medical Officer
8. Attorney Ellen Presby Joins The Nemeroff Law Firm In Dallas
9. Kevin Johnson Joins United Allergy Services Board Of Directors
10. Robert Funari Joins NxStage Board of Directors
11. B. Braun Joins National Health Organization Supporting Environmental Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017   Responding to Heath Ledger,s ... death of singer Chris Cornell in May, the ... offers a free online psychiatric drug side ... families about psychotropic drug risks. The father ... from an accidental overdose, has called for tighter rules on ...
(Date:6/7/2017)... Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), ... location. The Iowa ... 7 cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A ... "Our new cleanroom will allow ... Iowa patients," said Phil Rielly , ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
Breaking Medicine Technology:
(Date:6/23/2017)... , ... June 23, 2017 , ... Goodcents Deli Fresh ... The restaurant is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st ... of Graham Restaurant Group who owns three other locations in the Topeka and Bonner ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State ... 18 to 20. , The two-day conference is focused on advancing scientific knowledge ... improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... PureLife ... the endorsed amalgam separator supplier for CDA members. As part of the amalgam separator ... price of $99, saving more than $400 off the retail value. This partnership between ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland ... to 3 pm to present to graduate students exciting new and innovative hope research ... project led by The Health Improvement Service of the Western Health & Social Care ...
(Date:6/23/2017)... ... 2017 , ... All-Star Insurance, a family managed agency that offers insurance management ... announcing the launch of a new charity drive to benefit women in the area ... reveal that an estimated 252, 710 new cases of invasive or high risk breast ...
Breaking Medicine News(10 mins):